WO2002089832A3 - Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio. - Google Patents

Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio. Download PDF

Info

Publication number
WO2002089832A3
WO2002089832A3 PCT/DK2002/000295 DK0200295W WO02089832A3 WO 2002089832 A3 WO2002089832 A3 WO 2002089832A3 DK 0200295 W DK0200295 W DK 0200295W WO 02089832 A3 WO02089832 A3 WO 02089832A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulating
treating
preventing
ratio
sdf
Prior art date
Application number
PCT/DK2002/000295
Other languages
French (fr)
Other versions
WO2002089832A2 (en
Inventor
Tan Jinquan
Lars Kaergaard Poulsen
Original Assignee
Alk Abello As
Tan Jinquan
Lars Kaergaard Poulsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alk Abello As, Tan Jinquan, Lars Kaergaard Poulsen filed Critical Alk Abello As
Priority to CA002447360A priority Critical patent/CA2447360A1/en
Priority to JP2002586964A priority patent/JP2004536800A/en
Priority to EP02724144A priority patent/EP1418936A2/en
Publication of WO2002089832A2 publication Critical patent/WO2002089832A2/en
Publication of WO2002089832A3 publication Critical patent/WO2002089832A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Abstract

Pharmaceutical composition for preventing or treating a Th1 cell- or Th2-cell-related disease in a human or an animal by modulating the Th1/Th2 ratio comprising an active substance consisting of (i) IL-4 and SDF-1α, or IL-2 and SDF-1α, respectively, as well as modulators thereof, (ii) an IL-4 stimulating adjuvant and SDF-1α, or an IL-2 stimulating adjuvant and SDF-1α, respectively, (iii) a modulator of the tyrosine kinases Syk or ZAP-70, or (iv) a modulator of the nuclear factors of activated T cells NFAT1 or NFAT2.
PCT/DK2002/000295 2001-05-09 2002-05-07 Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio. WO2002089832A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002447360A CA2447360A1 (en) 2001-05-09 2002-05-07 Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.
JP2002586964A JP2004536800A (en) 2001-05-09 2002-05-07 Pharmaceutical composition for preventing or treating TH1 and TH2 cell-related diseases by modulating the TH1 / TH2 ratio
EP02724144A EP1418936A2 (en) 2001-05-09 2002-05-07 Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28971101P 2001-05-09 2001-05-09
DKPA200100726 2001-05-09
DKPA200100726 2001-05-09
US60/289,711 2001-05-09

Publications (2)

Publication Number Publication Date
WO2002089832A2 WO2002089832A2 (en) 2002-11-14
WO2002089832A3 true WO2002089832A3 (en) 2004-03-25

Family

ID=26069017

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000295 WO2002089832A2 (en) 2001-05-09 2002-05-07 Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.

Country Status (5)

Country Link
EP (1) EP1418936A2 (en)
JP (1) JP2004536800A (en)
CN (1) CN1531440A (en)
CA (1) CA2447360A1 (en)
WO (1) WO2002089832A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
EP2371835A1 (en) * 2003-07-03 2011-10-05 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
US20050191283A1 (en) * 2003-10-16 2005-09-01 Suzanne Kadereit Methods of treating NFAT-related disorders
JP2009155204A (en) * 2005-12-20 2009-07-16 Locomogene Inc Medicinal composition for allergic disease
TWI426918B (en) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Use of il-23 antagonists for treatment of infection
US9695397B2 (en) * 2008-10-01 2017-07-04 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy
WO2014172805A1 (en) * 2013-04-26 2014-10-30 Lee Der-Tsai Composition with improved cytokine activity, and application thereof
EP3467501B1 (en) 2014-05-16 2020-11-04 Amgen Inc. Assay for detecting th1 and th2 cell populations
CN104357392A (en) * 2014-11-07 2015-02-18 广州洁汉贸易有限公司 Method for polarizing CD4+T cell
CN104694631A (en) * 2015-02-05 2015-06-10 华中农业大学 Real-time fluorescence quantitative PCR analysis method for watermelon gene expression
CN108088998B (en) * 2016-11-23 2019-12-27 四川大学华西医院 Lung cancer screening kit
WO2021085576A1 (en) * 2019-11-01 2021-05-06 国立大学法人京都大学 Method for producing t cell
CN115927169B (en) * 2022-10-11 2023-08-11 再造再生医学科技(杭州)有限公司 For amplification of CD34 + Culture medium for hematopoietic stem cells and in vitro amplification of CD34 + Methods of hematopoietic stem cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040199A1 (en) * 1995-06-07 1996-12-19 University Of Pennsylvania Methods of inhibiting phagocytosis
WO2000024245A1 (en) * 1998-10-28 2000-05-04 President And Fellows Of Harvard College REGULATION OF TH2 CELL ACTIVITY BY MODULATION OF NFATp AND NFAT4 ACTIVITY

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69123361T2 (en) * 1990-09-06 1997-04-30 Schering Corp USE OF INTERLEUKIN-4 FOR TREATING SOLID TUMORS
EP0721340A1 (en) * 1991-03-07 1996-07-17 Seragen, Inc. Use of cell surface receptor targeted molecules for the treatment of viral diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040199A1 (en) * 1995-06-07 1996-12-19 University Of Pennsylvania Methods of inhibiting phagocytosis
WO2000024245A1 (en) * 1998-10-28 2000-05-04 President And Fellows Of Harvard College REGULATION OF TH2 CELL ACTIVITY BY MODULATION OF NFATp AND NFAT4 ACTIVITY

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHU D H ET AL: "THE SYK FAMILY OF PROTEIN TYROSINE KINASES IN T-CELL ACTIVATION AND DEVELOPMENT", IMMUNOLOGICAL REVIEWS, MUNKSGAARD, XX, vol. 165, 1998, pages 167 - 180, XP000985698, ISSN: 0105-2896 *
P. JOURDAN ET AL.: "CUTTING EDGE: IL-4 INDUCES FUNCTIONAL CELL-SURFACE EXPRESSION OF CXCR4 ON HUMAN T CELLS.", THE JOURNAL OF IMMUNOLOGY, vol. 160, 1998, BALTIMORE, US, pages 4153 - 4157, XP002195354 *
SOOMETS U ET AL: "ANTISENSE PROPERTIES OF PEPTIDE NUCLEIC ACIDS", FRONTIERS IN BIOSCIENCE, XX, XX, vol. 4, 1 November 1999 (1999-11-01), pages D782 - D786, XP001007169 *
T. NANKI ET AL.: "CUTTING EDGE: STROMAL CELL-DERIVED FACTOR -1 IS A COSTIMULATOR FOR CD4+ T CELL ACTIVATION.", THE JOURNAL OF IMMUNOLOGY, vol. 164, 2000, BALTIMORE, US, pages 5010 - 5014, XP002195353 *
T. TAMURA ET AL.: "EARLY ACTIVATION SIGNAL TRANSDUCTION PATHWAYS OF Th1 AND Th2 CELL CLONES STIMULATED WITH ANTI-CD3.", THE JOURNAL OF IMMUNOLOGY, vol. 155, 1995, BALTIMORE, US, pages 4692 - 4701, XP002195352 *

Also Published As

Publication number Publication date
CA2447360A1 (en) 2002-11-14
EP1418936A2 (en) 2004-05-19
JP2004536800A (en) 2004-12-09
CN1531440A (en) 2004-09-22
WO2002089832A2 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
WO2002089832A3 (en) Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.
WO2002087419A3 (en) Biological pacemaker
GEP20033092B (en) Purine Inhibitors of Cyclin Dependent Kinase 2 and Ik-Aa
EP2289939A3 (en) PAN-KIR2DL NK-receptor antibodies and their use in diagnostic and therapy
WO2005044179A3 (en) Formulations containing astragalus extracts and uses thereof
WO2003040144A3 (en) Heterocyclic compound based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds
YU49202A (en) Benzazole derivatives and their use as jnk modulators
WO2004052276A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002074156A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
IL173369A0 (en) Pharmaceutical combination of g-csf and plgf useful for blood stem cell
WO2004007682A3 (en) Methods and compositions for modulating t helper (th) cell development and function
IL180612A0 (en) Materials and methods for immune system stimulation
WO2002012328A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
IL156628A (en) Use of nk t cells in the preparation of a therapeutic composition, compositions comprising said nk t cells and their use in the treatment of immune-related disorders
AU2525301A (en) Genus leontopodium plant extract and compositions containing same
WO2005115346A3 (en) Pharmaceutical composition containing risperidone
EP1186292A3 (en) Solid composition with a multi-core structure
EP1519755A4 (en) Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
WO2003098223A3 (en) A method for killing cells by inhibiting histone activity in the cell
WO1999049876A3 (en) Bacterial or yeast extracts which stimulate the production of defensins and methods of use thereof
AU2002328873A1 (en) Dosage forms comprising particles containing active ingredient for application on the skin or mucous membrane
ATE245974T1 (en) PHARMACEUTICAL COMPOSITIONS INTENDED FOR THE ORAL ADMINISTRATION OF PHLOROGLUCINOL AND THE PRODUCTION THEREOF
WO2003086290A3 (en) Electroprocessing of materials useful in drug delivery and cell encapsulation
WO2002062203A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
BR0015422A (en) Prolonged-release drug formulations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002254873

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002586964

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2447360

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002724144

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 028133250

Country of ref document: CN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002724144

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002724144

Country of ref document: EP